MNM at the ESMO 2022 Congress

September 15, 2022
No items found.

At ESMO 2022 Congress in Paris the era of AI deployment continues.

Klaudia Pacewicz and Paulina Nawrocka-Muszynska presented preliminary findings showing how machine learning algorithms can predict response to immune checkpoint inhibitors (ICIs) with greater precision than any standard biomarkers. Our algorithm developed on non-small-cell lung carcinoma patients treated with pembrolizumab/nivolumab achieved great results with an accuracy of 0.88.

Incredible data emphasizing the power of genomic-based and AI research presented at ESMO makes us extremely excited about the future of the fight against cancer. We are so proud that our work actively contributes to the development of innovative medicine.

MNM at the ESMO 2022 Congress
September 22, 2022

You may also like

MNM's platform ARETE works!

MNM's platform ARETE - a proprietary AI technology designed for cancer genomics has been successfully externally validated by one of our Partners.

Professor Wojciech Niedzwiedz is joining our Scientific Advisory Board

Professor Wojciech Niedzwiedz from the Institute of Cancer Research and one of the top leaders in the field, is joining our Scientific Advisory Board.

Publication in Molecular Diagnosis & Therapy has been just released

MNM Biosciences, in co-operation with leading Polish cancer centers, has recently published a breakthrough publication concerning breast cancer diagnostics.

BiO€QUITY Europe on 17-19 May 2021

MNM Diagnostics has developed a unique AI-powered platform allowing for the rapid development of genome-based biomarkers providing an accurate prediction of the treatment outcomes for cancer patients.